加奈索酮
加奈索酮结构式
|
常用名 | 加奈索酮 | 英文名 | Ganaxolone |
|---|---|---|---|---|
| CAS号 | 38398-32-2 | 分子量 | 332.52000 | |
| 密度 | 1.036g/cm3 | 沸点 | 434.8ºC at 760mmHg | |
| 分子式 | C22H36O2 | 熔点 | N/A | |
| MSDS | 美版 | 闪点 | 185.4ºC |
|
A quantitiative LC-MS/MS method for the measurement of arachidonic acid, prostanoids, endocannabinoids, N-acylethanolamines and steroids in human plasma.
J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 976-977 , 6-18, (2015) Free arachidonic acid is functionally interlinked with different lipid signaling networks including those involving prostanoid pathways, the endocannabinoid system, N-acylethanolamines, as well as steroids. A sensitive and specific LC-MS/MS method for the qua... |
|
|
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.
Xenobiotica 35 , 191-210, (2005) The prediction of human pharmacokinetics is often based on in vivo preclinical pharmacokinetic data. However, to date, no clear guidance has been available about the relative ability of the major preclinical species to estimate human oral exposure. The study ... |
|
|
Endocannabinoid-mediated improvement on a test of aversive memory in a mouse model of fragile X syndrome.
Behav. Brain Res. 291 , 164-71, (2015) Silencing the gene FMR1 in fragile X syndrome (FXS) with consequent loss of its protein product, FMRP, results in intellectual disability, hyperactivity, anxiety, seizure disorders, and autism-like behavior. In a mouse model (Fmr1 knockout (KO)) of FXS, a def... |
|
|
A potential effect of ganaxolone in an animal model of infantile spasms
Epilepsy Res. 108(9) , 1492-500, (2014) • Ganaxolone pretreatment dose-dependently suppressed NMDA induced spasms in rats. • Randomized ganaxolone trial in rats with spasms was effective. • Ganaxolone treatment ameliorated the behavioral change after multiple NMDA spasms. • Ganaxolone can be a pote... |
|
|
Anticonvulsant doses of ganaxolone do not compromise motor performance in immature rats.
Neurosci. Lett. 469(3) , 396-9, (2010) Neuroactive steroids that function as positive modulators of GABA-A receptors are potential anticonvulsant drugs. We previously demonstrated that ganaxolone is effective against pentetrazol-induced motor seizures in immature rats. In the present study, we exa... |
|
|
A high-performance liquid chromatography-tandem mass spectrometric method for the determination of pharmacokinetics of ganaxolone in rat, monkey, dog and human plasma.
J. Chromatogr. B. Biomed. Sci. Appl. 751(1) , 49-59, (2001) A method for determining concentration levels of ganaxolone in rat, monkey, dog and human plasma was validated in the range of 5-1500 ng/ml using a 200-microl plasma sample volume. This validation report describes the linearity, specificity. sensitivity, repr... |
|
|
Ganaxolone.
Neurotherapeutics 4(1) , 102-5, (2007) Ganaxolone (3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one) (GNX) is the 3beta-methylated synthetic analog of allopregnanolone; it belongs to a class of compounds referred to as neurosteroids. GNX is an allosteric modulator of GABA(A) receptors acting thro... |
|
|
Effect of ganaxolone and THIP on operant and limited-access ethanol self-administration
Neuropharmacology 63(4) , 555-64, (2012) Recent evidence suggests that GABAA receptor ligands may regulate ethanol intake via effects at both synaptic and extrasynaptic receptors. For example, the endogenous neurosteroid, allopregnanolone (ALLO) has a similar pharmacological profile as ethanol, and ... |
|
|
Effects of some neurosteroids injected into some brain areas of WAG/Rij rats, an animal model of generalized absence epilepsy.
Neuropharmacology 50(8) , 1059-71, (2006) Neurosteroids are synthesized in the brain and have been demonstrated to modulate various cerebral functions. Allopregnanolone (3alpha-hydroxy-5alpha-pregnan-20-one), a naturally occurring neurosteroid, and ganaxolone (3alpha-hydroxy-3beta-methyl-5alpha-pregn... |
|
|
Clinical evaluation of ganaxolone in pediatric and adolescent patients with refractory epilepsy.
Epilepsia 48(10) , 1870-4, (2007) A pilot study of the safety, tolerability, dose range and potential efficacy of ganaxolone for the treatment of refractory epilepsy in pediatric and adolescent subjects.We report the results of a nonrandomized, nonblinded, open-label, dose-escalation trial of... |